Pharmacogenomics of oral antidiabetic medications: Current data and pharmacoepigenomic perspective

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1161-1191

  Manolopoulos, Vangelis G ^a   Ragia, Georgia ^a   Tavridou, Anna ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

antidiabetic; biguanides; epigenomics; metformin; pharmacoepigenomics; pharmacogenomics; repaglinide; sulfonylurea; thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

CHLORPROPAMIDE; FLUVOXAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MICRORNA; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TRIMETHOPRIM; TROGLITAZONE; UNCLASSIFIED DRUG;

ABCC8 GENE; AREA UNDER THE CURVE; ATM GENE; CALCIUM SIGNALING; CYP2C8 GENE; CYP2C9 GENE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG URINE LEVEL; DRUG WITHDRAWAL; EPIGENETICS; EVENING DOSAGE; GENE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLYCEMIC CONTROL; HETEROZYGOSITY; HUMAN; INSULIN RELEASE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OATP1B1 GENE; PHARMACOGENOMICS; PPAR GAMMA GENE; PREGNANCY DIABETES MELLITUS; REVIEW; SINGLE DRUG DOSE; SLC22A1 GENE; SLC22A2 GENE; SLCO1B1 GENE; TCFL2 GENE;

ADMINISTRATION, ORAL; ANIMALS; BIGUANIDES; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EPIGENOMICS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MICRORNAS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 80051766486     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.65     Document Type: Review

References (160)

1. Bergman RN, Finegood DT, Kahn SE. The evolution of b-cell dysfunction and insulin resistance in Type 2 diabetes. Eur. J. Clin. Invest. 32(Suppl. 3), 35-45 (2002). (Pubitemid 41704998)
2. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 26(2), 77-82 (2008). (Pubitemid 351556223)
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab. Care 32(1), 193-203 (2009).
4. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin. Chem. Lab. Med. 45(7), 801-814 (2007). (Pubitemid 47041905)
5. Pearson ER. Pharmacogenetics in diabetes. Curr. Diab. Rep. 9(2), 172-181 (2009).
6. Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin. Drug Metab. Toxicol. 4(5), 529-544 (2008). (Pubitemid 351890737)
7. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 8(8), 917-931 (2007). (Pubitemid 47423684)
8. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44(12), 1209-1225 (2005). (Pubitemid 41832564)
9. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin. Drug Metab. Toxicol. 5(3), 225-241 (2009).
10. Fowler GC, Vasudevan DA. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. South. Med. J. 103(9), 911-916 (2010).
11. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann. Med. 37(3), 186-195 (2005). (Pubitemid 40780436)
12. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res. Clin. Pract. 14(Suppl. 2), S21-S36 (1991).
13. Draeger E. Clinical profile of glimepiride. Diabetes Res. Clin. Pract. 28(Suppl), S139-S146 (1995).
14. Guiot Y, Stevens M, Marhfour I et al. Morphological localisation of sulfonylurea receptor 1 in endocrine cells of human, mouse and rat pancreas. Diabetologia 50(9), 1889-1899 (2007). (Pubitemid 47222851)
15. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 111(7), 405-414 (2003). (Pubitemid 37486432)
16. Niemi M, Cascorbi I, Timm R et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 72(3), 326-332 (2002).
17. Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12(2), 101-109 (2002). (Pubitemid 34298914)
18. Kirchheiner J, Brockmoller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71(4), 286-296 (2002). (Pubitemid 34311458)
19. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin. Pharmacol. Ther. 72(5), 562-571 (2002). (Pubitemid 36237728)
20. Becker ML, Visser LE, Trienekens PH et al. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther. 83(2), 288-292 (2008).
21. Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87(1), 52-56 (2010).
22. Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 11(11), 1517-1523 (2010).
23. Tan B, Zhang YF, Chen XY et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur. J. Clin. Pharmacol. 66(2), 145-151 (2010).
24. Holstein A, Plaschke A, Ptak M et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60(1), 103-106 (2005). (Pubitemid 40942788)
25. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10(11), 1781-1787 (2009).
26. Covvey JR, Lewis DA. Glimepiride-induced hypoglycemia with ciprofloxacin, metronidazole, and acute kidney injury. Hosp. Pharm. 45(12), 934-938 (2010).
27. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur. J. Clin. Pharmacol. 67(5), 471-476 (2011).
28. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15(6), 540-559 (2009).
29. Miki T, Nagashima K, Seino S. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic b-cells. J. Mol. Endocrinol. 22(2), 113-123 (1999). (Pubitemid 29193099)
30. van Dam RM, Hoebee B, Seidell JC et al. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet. Med. 22(5), 590-598 (2005). (Pubitemid 40593135)
31. Chistiakov DA, Potapov VA, Khodirev DC et al. Genetic variations in the pancreatic ATP-sensitive potassium channel, b-cell dysfunction, and susceptibility to Type 2 diabetes. Acta Diabetol. 46(1), 43-49 (2009).
32. Florez JC, Burtt N, de Bakker PI et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53(5), 1360-1368 (2004). (Pubitemid 38569024)
33. Hamming KS, Soliman D, Matemisz LC et al. Co-expression of the Type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 58(10), 2419-2424 (2009).
34. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in Type 2 diabetes. Diabetes Res. Clin. Pract. 77(1), 58-61 (2007). (Pubitemid 46590477)
35. Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care 31(10), 1939-1944 (2008).
36. Hansen T, Echwald SM, Hansen L et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47(4), 598-605 (1998). (Pubitemid 28160451)
37. Meirhaeghe A, Helbecque N, Cottel D et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am. J. Med. Genet. 101(1), 4-8 (2001). (Pubitemid 32429901)
38. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with Type 2 diabetes. Horm. Metab. Res. 41(5), 387-390 (2009).
39. Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 11(12), 1743-1750 (2010).
40. Sesti G, Marini MA, Cardellini M et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with Type 2 diabetes. Diabetes Care 27(6), 1394-1398 (2004). (Pubitemid 38679989)
41. Seeringer A, Parmar S, Fischer A et al. Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. Diabetes Obes. Metab. 12(12), 1106-1112 (2010).
42. Becker ML, Aarnoudse AJ, Newton-Cheh C et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet. Genomics 18(7), 591-597 (2008).
43. Cauchi S, El Achhab Y, Choquet H et al. TCF7L2 is reproducibly associated with Type 2 diabetes in various ethnic groups: a global meta-analysis. J. Mol. Med. 85(7), 777-782 (2007). (Pubitemid 47063530)
44. Kimber CH, Doney AS, Pearson ER et al. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 50(6), 1186-1191 (2007). (Pubitemid 46701564)
45. Meigs JB, Manning AK, Fox CS et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med. Genet. 8(Suppl. 1), S16 (2007).
46. Wen J, Ronn T, Olsson A et al. Investigation of Type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort. PLoS ONE 5(2), e9153 (2010).
47. Parikh H, Lyssenko V, Groop LC. Prioritizing genes for follow-up from genome wide association studies using information on gene expression in tissues relevant for Type 2 diabetes mellitus. BMC Med. Genomics 2, 72 (2009).
48. Takeuchi F, Serizawa M, Yamamoto K et al. Confirmation of multiple risk lLoci and genetic impacts by a genome-wide association study of Type 2 diabetes in the Japanese population. Diabetes 58(7), 1690-1699 (2009).
49. Guo T, Hanson RL, Traurig M et al. TCF7L2 is not a major susceptibility gene for Type 2 diabetes in Pima Indians: analysis of 3,501 individuals. Diabetes 56(12), 3082-3088 (2007). (Pubitemid 350223645)
50. Franklin CS, Aulchenko YS, Huffman JE et al. The TCF7L2 diabetes risk variant is associated with HbA(C) levels: a genome-wide association meta-analysis. Ann. Hum. Genet. 74(6), 471-478 (2010).
51. Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and Type 2 diabetes mellitus. Mol. Endocrinol. 22(11), 2383-2392 (2008).
52. Gaulton KJ, Nammo T, Pasquali L et al. A map of open chromatin in human pancreatic islets. Nat. Genet. 42(3), 255-259 (2010).
53. Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56(8), 2178-2182 (2007). (Pubitemid 47195841)
54. Schroner Z, Javorsky M, Tkacova R et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with Type 2 diabetes. Diabetes Obes. Metab. 13(1), 89-91 (2011).
55. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (2), CD004654 (2007).
56. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab. 32(2), 113-120 (2006).
57. Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin. Pharmacol. Toxicol. 107(4), 775-781 (2010).
58. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br. J. Clin. Pharmacol. 56(3), 305-314 (2003). (Pubitemid 37059658)
59. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 97(4), 249-256 (2005). (Pubitemid 41433700)
60. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74(4), 380-387 (2003). (Pubitemid 37222859)
61. Niemi M, Backman JT, Kajosaari LI et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77(6), 468-478 (2005). (Pubitemid 40824960)
62. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol. 66(6), 818-825 (2008).
63. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol. 48(3), 311-321 (2008). (Pubitemid 351257770)
64. Rodriguez-Antona C, Niemi M, Backman JT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8(4), 268-277 (2008). (Pubitemid 352038306)
65. Kirchheiner J, Meineke I, Muller G et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin. Pharmacokinet. 43(4), 267-278 (2004). (Pubitemid 38429306)
66. Sabia H, Sunkara G, Ligueros-Saylan M et al. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. Eur. J. Clin. Pharmacol. 60(6), 407-412 (2004). (Pubitemid 39214894)
67. Zhang W, He YJ, Han CT et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol. 62(5), 567-572 (2006). (Pubitemid 44571578)
68. He YY, Zhang R, Shao XY et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol. Sin. 29(8), 983-989 (2008).
69. Bosi E. Metformin-the gold standard in Type 2 diabetes: what does the evidence tell us? Diabetes Obes. Metab. 11(Suppl. 2), 3-8 (2009).
70. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16(3), 195-202 (1979). (Pubitemid 10227380)
71. Ciarimboli G. Organic cation transporters. Xenobiotica 38(7-8), 936-971 (2008).
72. Shikata E, Yamamoto R, Takane H et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 52(2), 117-122 (2007). (Pubitemid 46185105)
73. Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117(5), 1422-1431 (2007). (Pubitemid 46718430)
74. Shu Y, Brown C, Castro RA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2), 273-280 (2008).
75. Tzvetkov MV, Vormfelde SV, Balen D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86(3), 299-306 (2009).
76. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 18(7), 637-645 (2008).
77. Chen Y, Li S, Brown C et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 19(7), 497-504 (2009).
78. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogen. J. 9(4), 242-247 (2009).
79. Becker ML, Visser LE, van Schaik RH et al. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes. a preliminary study. Diabetes 58(3), 745-749 (2009).
80. Becker ML, Visser LE, van Schaik RH et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet. Genomics 20(1), 38-44 (2010).
81. Jablonski KA, McAteer JB, de Bakker PI et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59(10), 2672-2681 (2010).
82. Zhou K, Bellenguez C, Spencer CC et al. Common variants near ATM are associated with glycemic response to metformin in Type 2 diabetes. Nat. Genet. 43(2), 117-120 (2011).
83. Picard F, Auwerx J. PPAR(g) and glucose homeostasis. Annu. Rev. Nutr. 22, 167-197 (2002).
84. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr. Pharm. Des. 15(27), 3179-3192 (2009).
85. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in Type 2 diabetes. Lancet 373(9681), 2088-2090 (2009).
86. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427-2443 (2006). (Pubitemid 44903747)
87. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. 48(3), 424-432 (1999). (Pubitemid 29417728)
88. Bachmakov I, Glaeser H, Fromm MF, Konig J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57(6), 1463-1469 (2008).
89. Hruska MW, Amico JA, Langaee TY et al. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br. J. Clin. Pharmacol. 59(1), 70-79 (2005). (Pubitemid 40040098)
90. Pedersen RS, Damkier P, Brosen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br. J. Clin. Pharmacol. 62(6), 682-689 (2006). (Pubitemid 44749545)
91. Kirchheiner J, Thomas S, Bauer S et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80(6), 657-667 (2006). (Pubitemid 44920222)
92. Aquilante CL, Bushman LR, Knutsen SD et al. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics. 3(1), 7-16 (2008).
93. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br. J. Clin. Pharmacol. 65(1), 78-86 (2008). (Pubitemid 350265174)
94. Kang ES, Park SY, Kim HJ et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with Type 2 diabetes. Diabetes Care 28(5), 1139-1144 (2005).
95. Kang ES, Park SY, Kim HJ et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor g2 gene on rosiglitazone response in Type 2 diabetes. Clin. Pharmacol. Ther. 78(2), 202-208 (2005).
96. Kang ES, Park SE, Han SJ et al. LPIN1 genetic variation is associated with rosiglitazone response in Type 2 diabetic patients. Mol. Genet. Metab. 95(1-2), 96-100 (2008).
97. Kang ES, Cha BS, Kim HJ et al. The 11482G
98. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin. Pharmacol. Toxicol. 99(1), 44-51 (2006). (Pubitemid 44034394)
99. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos. 36(1), 73-80 (2008).
100. Ramirez-Salazar M, Perez-Luque E, Fajardo-Araujo M, Garza SM, Malacara JM. Effect of the Pro12Ala polymorphism of the PPAR g 2 gene on response to pioglitazone treatment in menopausal women. Menopause 15(6), 1151-1156 (2008).
101. Hsieh MC, Lin KD, Tien KJ et al. Common polymorphisms of the peroxisome proliferator-activated receptor-g (Pro12Ala) and peroxisome proliferator- activated receptor-g coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with Type 2 diabetes mellitus. Metabolism 59(8), 1139-1144 (2010).
102. Mathur SK, Rathore R, Chandra S et al. Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-g gene. Indian J. Physiol. Pharmacol. 53(2), 175-180 (2009).
103. Wang G, Wang X, Zhang Q, Ma Z. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with Type 2 diabetes mellitus. Int. J. Clin. Pract. 61(4), 552-557 (2007). (Pubitemid 46449814)
104. Li Z, Peng X, Wu Y, Xia Y, Liu X, Zhang Q. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with Type 2 diabetes. Diabetes Obes. Metab. 10(9), 794-802 (2008).
105. Makino H, Shimizu I, Murao S et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at-420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in Type 2 diabetes. Endocr. J. 56(9), 1049-1058 (2009).
106. Azen SP, Peters RK, Berkowitz K et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control. Clin. Trials 19(2), 217-231 (1998). (Pubitemid 28191975)
107. Knowler WC, Hamman RF, Edelstein SL et al. Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54(4), 1150-1156 (2005). (Pubitemid 40446330)
108. Wolford JK, Yeatts KA, Dhanjal SK et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54(11), 3319-3325 (2005). (Pubitemid 43334389)
109. Florez JC, Jablonski KA, Sun MW et al. Effects of the Type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab. 92(4), 1502-1509 (2007). (Pubitemid 46556431)
110. Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol. In vitro 23(7), 1387-1395 (2009).
111. Siest G, Marteau JB, Maumus S et al. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. 527(1-3), 1-22 (2005). (Pubitemid 41745146)
112. Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Medical hypotheses 73(5), 770-780 (2009).
113. Goh KP, Sum CF. Connecting the dots: molecular and epigenetic mechanisms in Type 2 diabetes. Curr. Diabetes Rev. 6(4), 255-265 (2010).
114. Kim E. Insulin resistance at the crossroads of metabolic syndrome: systemic analysis using microarrays. Biotechnol. J. 5(9), 919-929 (2010).
115. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 174(3), 341-348 (2006). (Pubitemid 43235307)
116. Ekstrom TJ. Epigenetic control of gene expression. Biochim. Biophys. Acta 1790(9), 845-846 (2009).
117. Korber P, Becker PB. Nucleosome dynamics and epigenetic stability. Essays Biochem. 48(1), 63-74 (2010).
118. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol. Cell Biol. 22(9), 3157-3173 (2002). (Pubitemid 34437474)
119. Prokhortchouk E, Defossez PA. The cell biology of DNA methylation in mammals. Biochim. Biophys. Acta 1783(11), 2167-2173 (2008).
120. Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct. Genomic Proteomic 5(3), 190-208 (2006). (Pubitemid 46470220)
121. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12(5), 599-606 (1998). (Pubitemid 28134293)
122. Delcuve GP, Rastegar M, Davie JR. Epigenetic control. J. Cell Physiol. 219(2), 243-250 (2009).
123. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem Cell Biol. 41(1), 87-95 (2009).
124. Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 7(4), 147-154 (2009).
125. Ingelman-Sundberg M, Sim SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 396(1), 90-94 (2010).
126. Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics 11(5), 629-632 (2010).
127. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10(3), 399-416 (2009).
128. Ingelman-Sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics 11(5), 625-627 (2010).
129. Muller G. Personalized prognosis and diagnosis of Type 2 diabetes-vision or fiction? Pharmacology 85(3), 168-187 (2010).
130. McCarthy MI, Zeggini E. Genome-wide association studies in Type 2 diabetes. Curr. Diab. Rep. 9(2), 164-171 (2009).
131. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ. Res. 107(12), 1403-1413 (2010).
132. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 107(9), 1058-1070 (2010).
133. Cerda S, Weitzman SA. Influence of oxygen radical injury on DNA methylation. Mutat. Res. 386(2), 141-152 (1997). (Pubitemid 27195019)
134. Wu J, Basha MR, Zawia NH. The environment, epigenetics and amyloidogenesis. J. Mol. Neurosci. 34(1), 1-7 (2008). (Pubitemid 351378089)
135. Brealey D, Singer M. Hyperglycemia in critical illness: a review. J. Diabetes Sci. Technol. 3(6), 1250-1260 (2009).
136. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr. Pharm. Des. 14(10), 962-968 (2008). (Pubitemid 351753283)
137. Krajcovicova-Kudlackova M, Sebekova K, Schinzel R, Klvanova J. Advanced glycation end products and nutrition. Physiol. Res. 51(3), 313-316 (2002). (Pubitemid 34970187)
138. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010, 792393 (2010).
139. Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J. Biol. Chem. 282(18), 13854-13863 (2007). (Pubitemid 47100501)
140. Ling C, Del Guerra S, Lupi R et al. Epigenetic regulation of PPARGC1A in human Type 2 diabetic islets and effect on insulin secretion. Diabetologia 51(4), 615-622 (2008).
141. Kong L, Zhu J, Han W et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed Type 2 diabetes: a clinical study. Acta Diabetol. 48(1), 61-69 (2011).
142. Rosero S, Bravo-Egana V, Jiang Z et al. MicroRNA signature of the human developing pancreas. BMC Genomics 11, 509 (2010).
143. Zampetaki A, Kiechl S, Drozdov I et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in Type 2 diabetes. Circ. Res. 107(6), 810-817 (2010).
144. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res. Clin. Pract. 91(1), 94-100 (2011).
145. Caporali A, Meloni M, Vollenkle C et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123(3), 282-291 (2011).
146. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28(11), 570-579 (2010).
147. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol. 79(7), 1045-1052 (2010).
148. Devlin AH, Thompson P, Robson T, McKeown SR. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol. Carcinog. 49(2), 190-199 (2010).
149. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 10(7), 1067-1076 (2009).
150. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug. Metab. Dispos. 37(10), 2112-2117 (2009).
151. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66(18), 9090-9098 (2006). (Pubitemid 44521128)
152. Barros SP, Offenbacher S. Epigenetics: connecting environment and genotype to phenotype and disease. J. Dent. Res. 88(5), 400-408 (2009).
153. Schumacher A, Petronis A. Epigenetics of complex diseases: from general theory to laboratory experiments. Curr. Top. Microbiol. Immunol. 310, 81-115 (2006). (Pubitemid 47400287)
154. Muhonen P, Holthofer H. Epigenetic and microRNA-mediated regulation in diabetes. Nephrol. Dial. Transplant. 24(4), 1088-1096 (2009).
155. Correa-Medina M, Bravo-Egana V, Rosero S et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr. Patterns 9(4), 193-199 (2009).
156. Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and Mir-9 expressions are regulated during glucose stimulated insulin secretion in pancreatic b-islets. FEBS J. 278(7), 1167-1174 (2011).
157. Joglekar MV, Patil D, Joglekar VM et al. The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 1(2), 137-147 (2009).
158. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 58(5), 1050-1057 (2009).
159. Fred RG, Bang-Berthelsen CH, Mandrup-Poulsen T, Grunnet LG, Welsh N. High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression. PLoS ONE 5(5), e10843 (2010).
160. Poy MN, Hausser J, Trajkovski M et al. miR-375 maintains normal pancreatic a-and b-cell mass. Proc. Natl. Acad. Sci. USA 106(14), 5813-5818 (2009).